James Benjamin Galloway
Impact in
- Rheumatology top 0.1%
- Rheumatoid Arthritis Research and Therapies
- Systemic Lupus Erythematosus Research
- Spondyloarthritis Studies and Treatments
- Infectious Diseases top 1%
- COVID-19 Clinical Research Studies
- SARS-CoV-2 and COVID-19 Research
- Tuberculosis Research and Epidemiology
Papers in
- Rheumatology 155
- Rheumatoid Arthritis Research and Therapies 131
- Systemic Lupus Erythematosus Research 24
- Spondyloarthritis Studies and Treatments 16
- Hematology 22
- Autoimmune and Inflammatory Disorders Research 19
- Co-authors
- Kimme Leanne Hyrich (26 shared papers)Mark Lunt (16 shared papers)Deborah P. M. Symmons (14 shared papers)Kath D. Watson (13 shared papers)William Gregory Dixon (10 shared papers)Andrew Ustianowski (6 shared papers)Katie Bechman (51 shared papers)Sam Norton (84 shared papers)
- Journals
- Lara D. Veeken (96 papers)Annals of the Rheumatic Diseases (19 papers)The Journal of Rheumatology (12 papers)RMD Open (11 papers)The Lancet Rheumatology (11 papers)
- Partner nations
- United KingdomUnited StatesItaly
In The Last Decade
James Benjamin Galloway
305 papers receiving 9.3k citations
James Benjamin Galloway's Hit Papers
Peers
Comparison fields: 5 of 155
- Rheumatology 3.0k
- Infectious Diseases 2.2k
- Hematology 808
- Neurology 798
- Immunology 1.0k
Countries citing papers authored by James Benjamin Galloway
This map shows the geographic impact of James Benjamin Galloway's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by James Benjamin Galloway with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites James Benjamin Galloway more than expected).
Fields of papers citing papers by James Benjamin Galloway
This network shows the impact of papers produced by James Benjamin Galloway. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by James Benjamin Galloway. The network helps show where James Benjamin Galloway may publish in the future.
Co-authors
The 25 scholars most cited alongside James Benjamin Galloway, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 343 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register (BSRBR) Hit paper breakdown → | 2009 | 600 |
| 2 | Anti-TNF therapy is associated with an increased risk of serious infections in patients with rheumatoid arthritis especially in the first 6 months of treatment: updated results from the British Society for Rheumatology Biologics Register with special emphasis on risks in the elderly Hit paper breakdown → | 2010 | 553 |
| 3 | Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial Hit paper breakdown → | 2021 | 403 |
| 4 | Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial Hit paper breakdown → | 2021 | 381 |
| 5 | Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial Hit paper breakdown → | 2022 | 282 |
| 6 | Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis Hit paper breakdown → | 2022 | 230 |
| 7 | A systematic review and meta-analysis of infection risk with small molecule JAK inhibitors in rheumatoid arthritis Hit paper breakdown → | 2019 | 224 |
| 8 | 2016 | 217 | |
| 9 | Aspirin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial Hit paper breakdown → | 2021 | 211 |
| 10 | 2020 | 167 | |
| 11 | 2011 | 163 | |
| 12 | 2012 | 141 | |
| 13 | 2018 | 137 | |
| 14 | 2022 EULAR recommendations for screening and prophylaxis of chronic and opportunistic infections in adults with autoimmune inflammatory rheumatic diseases Hit paper breakdown → | 2022 | 135 |
| 15 | 2021 | 134 | |
| 16 | 2020 | 131 | |
| 17 | 2020 | 125 | |
| 18 | Abatacept in individuals at high risk of rheumatoid arthritis (APIPPRA): a randomised, double-blind, multicentre, parallel, placebo-controlled, phase 2b clinical trial Hit paper breakdown → | 2024 | 123 |
| 19 | 2012 | 120 | |
| 20 | 2017 | 118 |
About James Benjamin Galloway
James Benjamin Galloway is a scholar working on Rheumatology, Hematology, Infectious Diseases, Immunology and Nephrology, having authored 343 papers that have together received 9.6k indexed citations. Recurring topics across this work include Rheumatoid Arthritis Research and Therapies (131 papers), Systemic Lupus Erythematosus Research (24 papers), Autoimmune and Inflammatory Disorders Research (19 papers), Spondyloarthritis Studies and Treatments (16 papers), Sarcoidosis and Beryllium Toxicity Research (14 papers), COVID-19 Clinical Research Studies (12 papers), SARS-CoV-2 and COVID-19 Research (12 papers) and Psoriasis: Treatment and Pathogenesis (9 papers). The work is most often cited by research in Rheumatology (3.0k citations), Infectious Diseases (2.2k citations), Hematology (808 citations), Neurology (798 citations) and Immunology (1.0k citations). James Benjamin Galloway has collaborated with scholars based in United Kingdom, United States and Italy. Frequent co-authors include Kimme Leanne Hyrich, Mark Lunt, Deborah P. M. Symmons, Kath D. Watson, William Gregory Dixon, Andrew Ustianowski, Katie Bechman, Sam Norton, Louise Mercer and Sujith Subesinghe. Their work appears in journals such as Lara D. Veeken, Annals of the Rheumatic Diseases, The Journal of Rheumatology, RMD Open and The Lancet Rheumatology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.